Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Globally, much morbidity and premature mortality arises from coronary artery disease (CAD).
Coronary artery atherothrombosis is the dominant cause of acute coronary syndromes …

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of
the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in …

Eicosanoid signaling controls a wide range of biological processes from blood pressure
homeostasis to inflammation and resolution thereof to the perception of pain and to cell …

Cessation of one component of dual antiplatelet therapy (DAPT) following percutaneous
coronary intervention (PCI) has been associated with increased risk of ischemic events but it …

The cause of atherothrombosis is rupture or erosion of atherosclerotic lesions, leading to an
increased risk of myocardial infarction or stroke. Here, platelet activation plays a major role …

In recent years, much progress has been made in the field of antithrombotic drugs in acute
coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent …

Selatogrel, a potent and reversible antagonist of the P2Y12 receptor, inhibited FeCl3-
induced thrombosis in rats. Here, we report the anti-thrombotic effect of selatogrel after …

Background The enhanced thrombotic milieu in diabetes contributes to increased risk of
vascular events. Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in …

Stroke is a common and devastating condition caused by atherothrombosis,
thromboembolism, or haemorrhage. Patients with chronic coronary syndromes (CCS) or …